Dimerix (ASX:DXB) said that a total of 200 adult patients were randomized and dosed in its Action3 phase three clinical trial in patients with focal segmental glomerulosclerosis, representing around 70% of the total number of patients to be dosed in the two-year study, according to a Friday Australian bourse filing.

The firm is targeting a total recruitment of around 286 adult patients. Full recruitment of patients into the trial is on track for the second half.

The trial is seeking to evaluate the efficacy and safety of the firm's DMX200 treatment candidate in patients with focal segmental glomerulosclerosis, a kidney disease, the filing said. The participants are receiving a stable dose of an angiotensin II receptor blocker, and once this dose is stable, patients will be randomized to receive either DMX200 or a placebo.

The trial is designed to capture evidence of kidney function and high levels of protein in the urine, which will be used as evidence to support marketing approval. The company has activated over 190 clinical sites in 22 countries.

The company's shares fell over 5% in recent trading on Friday.